Abstract 658P
Background
Oncolytic viruses have the potential to synergize with immune checkpoint inhibitors (ICI), especially when engineered to express immunomodulatory payloads. ONCR-177 is a next-generation oncolytic Herpes Simplex Virus-1 (oHSV-1) intended for intratumoral (IT) administration, developed to target solid tumors, in monotherapy and in combination with ICI.
Methods
A first-in-human phase 1 trial (NCT04348916) of IT ONCR-177 alone and in combination with pembrolizumab in patients (pts) with advanced cutaneous, subcutaneous or metastatic solid tumors (surface lesions), and liver metastases (visceral lesions) was performed. Primary objectives were safety, tolerability, and determination of the recommended Phase 2 dose (RP2D) of ONCR-177 alone and in combination with pembrolizumab. Secondary objectives were anti-tumor activity (RECIST v1.1), viral shedding and cytokine levels detection.
Results
A total of 66 pts, with a median age of 63, 55% females and with 13 different tumor types (most frequent breast cancer 30%) were enrolled (N=56 in surface and N=10 in visceral lesions cohort). Sixty-two pts were evaluable for safety. No dose-limiting toxicities (DLTs) were reported through different dose levels (DL) up to 4x108 PFU in 4ml, which was defined as RP2D. The most common treatment-related adverse events (TRAEs) were cytokine release syndrome (CRS), in 14 pts (23%) or symptoms of fever, hypotension, and chills in 32 pts (52%). Only 1 pt had grade (G)3 CRS. Other TRAEs included G1/2 fatigue (37%). A total of 61 pts were evaluable for response, with 5 responders, all at RP2D and in surface lesions, 3 (5%) complete responses (CR) and 2 (3%) partial responses (PR), all previously exposed to ICI. Two CR were achieved in combination cohort. At RP2D, a trend towards higher plasma IFNγ levels and CRS-related AEs was observed, although no payload above physiologically relevant levels was detected.
Conclusions
ONCR-177 was safe to administer to surface and visceral lesions either as monotherapy or in combination with Pembrolizumab. Local responses were observed, although sustainable efficacy could not be achieved in a systemic manner in these heavily pretreated pts.
Clinical trial identification
NCT04348916.
Editorial acknowledgement
Legal entity responsible for the study
Oncorus.
Funding
Oncorus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01